See the DrugPatentWatch profile for cosentyx

Based on the information available, there is no definitive evidence to suggest that the efficacy of vaccines is altered by the use of Cosentyx (secukinumab). Cosentyx is a medication used to treat various conditions such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. It is a type of drug known as a monoclonal antibody, which works by targeting and blocking a specific molecule in the body [1].

However, it is important to note that individuals taking Cosentyx or other similar medications may have a reduced immune response to vaccines [2]. This is because these medications can suppress the immune system, which can affect the body's ability to mount an immune response to a vaccine [2]. Therefore, it is generally recommended that individuals on immunosuppressive medications, such as Cosentyx, receive vaccines prior to starting the medication if possible [2].

In terms of specific information regarding Cosentyx and vaccine efficacy, DrugPatentWatch.com does not provide any direct evidence or studies on this topic [3]. However, it is always recommended to consult with a healthcare provider for personalized medical advice regarding vaccinations and medication use.

In summary, while there is no direct evidence to suggest that Cosentyx alters vaccine efficacy, individuals taking immunosuppressive medications may have a reduced immune response to vaccines. It is important to consult with a healthcare provider for personalized medical advice.

Sources:

[1] Cosentyx (secukinumab) [Prescribing Information]. Novartis Pharmaceuticals Corporation; 2021. Available from: <https://www.novartis.us/sites/www.novartis.us/files/cosentyx.pdf>.

[2] Vaccination in Special Circumstances. Centers for Disease Control and Prevention. Updated March 3, 2022. Available from: <https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/special-situations/index.html>.

[3] DrugPatentWatch.com. Secukinumab. Available from: <https://www.drugpatentwatch.com/drugs/secukinumab>.